LEUKOCARE to receive Frost & Sullivan’s 2011 Biotechnology Investment Opportunity Award
LEUKOCARE has been awarded 2011’s “biotechnology Investment Opportunity Award”, by the independent research consultancy Frost & Sullivan.
In the citation for the 2011 European Biotechnology Industry Early Stage Investment Opportunity Award, Frost & Sullivan focuses on the innovative nature of LEUKOCARE’s Stabilizing and Protecting Solutions (SPS) and the company’s strong strategic position in fast growing markets. The award report concludes: “LEUKOCARE, by way of its early mover advantage, its path breaking technology and sound management backing, is well positioned to be the recipient of Frost & Sullivan’s ‘Investment Opportunity’ award.”
“We are honoured that distinguished global analyst firm Frost & Sullivan recognises our achievements and emphasizes the outstanding value our expertise has created by helping companies maintain the stability, sterility, and shelf life of their delicate biological molecules,” says Michael Scholl, CEO with LEUKOCARE. “This prestigious award gives us a tremendous incentive to forge ahead, especially in fast growing markets, where we have already made great progress.”
Other news from the department business & finance
